Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016

  • ID: 3743720
  • Drug Pipelines
  • 54 pages
  • Global Markets Direct
1 of 6

FEATURED COMPANIES

  • AFFiRiS AG
  • Neurimmune Holding AG
  • nLife Therapeutics, S.L.
  • reMYND NV
  • Sangamo BioSciences, Inc.
  • UniQure N.V.
  • MORE
Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016

Summary

‘Huntingtin (Huntington Disease Protein) - Pipeline Review, H1 2016’, provides in depth analysis on Huntingtin (Huntington Disease Protein) targeted pipeline therapeutics.

The report provides comprehensive information on the Huntingtin (Huntington Disease Protein), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics development and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Huntingtin (Huntington Disease Protein)
- The report reviews Huntingtin (Huntington Disease Protein) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics and enlists all their major and minor projects
- The report assesses Huntingtin (Huntington Disease Protein) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Huntingtin (Huntington Disease Protein) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Huntingtin (Huntington Disease Protein)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Huntingtin (Huntington Disease Protein) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
READ MORE
Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • AFFiRiS AG
  • Neurimmune Holding AG
  • nLife Therapeutics, S.L.
  • reMYND NV
  • Sangamo BioSciences, Inc.
  • UniQure N.V.
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Huntingtin (Huntington Disease Protein) Overview

Therapeutics Development

Huntingtin (Huntington Disease Protein) - Products under Development by Stage of Development

Huntingtin (Huntington Disease Protein) - Products under Development by Therapy Area

Huntingtin (Huntington Disease Protein) - Products under Development by Indication

Huntingtin (Huntington Disease Protein) - Pipeline Products Glance

Late Stage Products

Early Stage Products

Huntingtin (Huntington Disease Protein) - Products under Development by Companies

Huntingtin (Huntington Disease Protein) - Therapeutics Assessment

Assessment by Monotherapy/Combination Products

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Huntingtin (Huntington Disease Protein) - Companies Involved in Therapeutics Development

AFFiRiS AG

Ionis Pharmaceuticals, Inc.

Neurimmune Holding AG

nLife Therapeutics, S.L.

reMYND NV

Sangamo BioSciences, Inc.

UniQure N.V.

Voyager Therapeutics, Inc.

Vybion, Inc.

WAVE Life Sciences Ltd.

Huntingtin (Huntington Disease Protein) - Drug Profiles

AMT-130 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide 1 to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide 2 to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit HTT for Huntington's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotides to Inhibit Huntingtin Protein for Huntington's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gene Therapy to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INT-41 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-HTTRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NI-302 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Huntingtin Protein for Huntington’s Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target Huntingtin for Huntington's Disease - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VYHTT-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Huntingtin (Huntington Disease Protein) - Dormant Projects

Huntingtin (Huntington Disease Protein) - Featured News & Press Releases

Mar 22, 2016: uniQure Announces Preclinical Proof of Concept for Gene Therapy Approach in Huntington’s Disease

Jan 05, 2016: Ionis Pharmaceuticals Receives Orphan Drug Designation from the US FDA for IONIS-HTT Rx for the Treatment of Patients with Huntington Disease

Jul 21, 2015: Isis Pharmaceuticals Initiates Clinical Study of ISIS-HTT Rx in Patients With Huntington's Disease

Nov 19, 2014: Sangamo BioSciences Presents Study At Society For Neuroscience Meeting Demonstrating In Vivo Reversal Of Huntington's Disease Signs And Symptoms

Nov 12, 2013: Sangamo BioSciences Announces Presentation Of First Demonstration Of In Vivo Efficacy Of Novel ZFP Therapeutic For Huntington's Disease

Sep 03, 2013: Vybion’s Huntington Drug Neutralizes Critical Disease Driver

Oct 17, 2012: Sangamo BioSciences Announces First Presentation Of Data From ZFP Therapeutic For Huntington's Disease At 2012 Annual Meeting Of Society For Neuroscience

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Indication, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Number of Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Pipeline by AFFiRiS AG, H1 2016

Pipeline by Ionis Pharmaceuticals, Inc., H1 2016

Pipeline by Neurimmune Holding AG, H1 2016

Pipeline by nLife Therapeutics, S.L., H1 2016

Pipeline by reMYND NV, H1 2016

Pipeline by Sangamo BioSciences, Inc., H1 2016

Pipeline by UniQure N.V., H1 2016

Pipeline by Voyager Therapeutics, Inc., H1 2016

Pipeline by Vybion, Inc., H1 2016

Pipeline by WAVE Life Sciences Ltd., H1 2016

Dormant Projects, H1 2016

List of Figures

Number of Products under Development for, H1 2016

Number of Products under Development by Therapy Area, H1 2016

Number of Products under Development by Top 10 Indication, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy/Combination Products, H1 2016

Number of Products by Stage and Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Type, H1 2016
Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • AFFiRiS AG
  • Neurimmune Holding AG
  • nLife Therapeutics, S.L.
  • reMYND NV
  • Sangamo BioSciences, Inc.
  • UniQure N.V.
  • MORE
According to our recently published report 'Huntingtin (Huntington Disease Protein) – Pipeline Review, H1 2016'; Huntingtin (Huntington Disease Protein) pipeline Target constitutes close to 12 molecules. Out of which approximately 12 molecules are developed by Companies.

Furthermore, the publisher says; Huntingtin (Huntington Disease Protein) Huntingtin protein is an encoded by the huntingtin gene, also called the HTT or HD (Huntington disease) gene. Huntingtin up regulates the expression of brain derived neurotrophic factor (BDNF) at the transcription level. Huntingtin is primarily associated with vesicles and microtubules. These indicate an important role in cytoskeletal anchoring or transport of mitochondria. The Htt protein is involved in vesicle trafficking as it interacts with HIP1 to mediate endocytosis. Huntingtin also plays an important role in the establishment in epithelial polarity through its interaction with RAB11A.

The report 'Huntingtin (Huntington Disease Protein) – Pipeline Review, H1 2016' outlays comprehensive information on the Huntingtin (Huntington Disease Protein) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Huntingtin (Huntington Disease Protein) targeted therapeutics development, features dormant and discontinued projects and latest news and press releases. Currently, The molecules developed by Companies in Phase II, Preclinical and Discovery stages are 1, 7 and 4 respectively.
Note: Product cover images may vary from those shown
5 of 6
AFFiRiS AG
Ionis Pharmaceuticals, Inc.
Neurimmune Holding AG
nLife Therapeutics, S.L.
reMYND NV
Sangamo BioSciences, Inc.
UniQure N.V.
Voyager Therapeutics, Inc.
Vybion, Inc.
WAVE Life Sciences Ltd.
Note: Product cover images may vary from those shown
6 of 6
Note: Product cover images may vary from those shown
Adroll
adroll